Skip to the guide
EXACT 41

Synaptic signalling research / EDUCATIONAL GUIDE

Dihexa

Dihexa 5 mg box packaging mockup
Packaging mockup
5 mg€39.90

Research aims, observed effects
and the limits of the evidence.

Preclinical evidence; source concernSources checked 6 September 2026

THE IDEA IN EVERYDAY TERMS

Connections between brain cells and memory

Dihexa has been investigated for effects on synapses—the junctions through which nerve cells communicate. The cited preclinical paper proposed an interaction with HGF/c-Met, a growth-factor signalling system, and reported changes in synapse-related measures. The question is whether those observations can inform research into cognitive problems.

Read the background ↗

Preclinical paper with an expression of concern

What has actually been shown?

Cell and animal observations do not demonstrate better memory or a dementia treatment in people. The cited paper also has a published expression of concern, which adds an important reason to treat its findings cautiously. The research reviewed here does not establish human efficacy or long-term safety, and does not support describing Dihexa as a proven cognitive enhancer.

Read the evidence ↗

A qualification attached to the source

The journal published a notice of concern in 2021 about the 2014 paper cited in this guide. Read that notice alongside the study; the proposed mechanism and reported effects should not be presented as settled findings. Read the source ↗

01 / OVERVIEW

What is Dihexa?

Dihexa is an angiotensin-IV-derived experimental compound studied in cellular and animal neuroscience models. [1]

02 / RESEARCH AIMS

Why it is studied.

Researchers investigated synapse formation and cognitive-related models, seeking to understand possible HGF/c-Met signalling effects. [1]

03 / RESEARCH MAP

Following the research question.

The cited study reported binding to hepatocyte growth factor and enhancement of HGF-dependent c-Met activation. This proposed preclinical mechanism comes from a paper with a published expression of concern; it is not established cognitive enhancement in humans. [1]

Dihexa research map: Dihexa; HGF / c-Met research; Synapse-related endpointsRESEARCH MAP / DIHEXA01Dihexa02HGF / c-Met research03Synapse-related endpoints
Conceptual research map, not a molecular structure or a proven chain of clinical effects. [1]

04 / OBSERVED EFFECTS

What the evidence shows.

The cited paper, which has a published expression of concern, reported changes in synapse-related measures. Such laboratory observations do not establish a treatment for dementia or an improvement in everyday human cognition. [1]

Study context

Cellular / animal models

Key distinction

Mechanistic observations

Uncertainty

Human evidence gap

A selected-source overview, not a systematic review. Research findings are not verified effects of an independently supplied sample.

05 / SAFETY AND LIMITATIONS

Risks belong beside the findings.

FDA reports no identified human exposure data and important unresolved safety questions. [2]

Human efficacy, long-term safety and consequences of altering this growth-factor pathway remain unresolved.

06 / REFERENCES

Go to the source.

  1. Dihexa and the HGF/c-Met system ↗

    Journal of Pharmacology and Experimental Therapeutics, 2014. Preclinical study with a published expression of concern.

  2. FDA — Safety concerns for certain compounded substances ↗

    Regulatory safety assessment; route and formulation matter.

  3. Notice of concern for the 2014 Dihexa study ↗

    Journal of Pharmacology and Experimental Therapeutics, 2021. Read alongside the original paper.